The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats

British Journal of Pharmacology

Volumn 135, Issue 1, 2002, Pages 170-180

  Mechan, Annis O ^a   Esteban, Blanca ^a,b   O'Shea, Esther ^b   Elliott, J Martin ^a   Colado, M Isabel ^b   Green, A Richard ^a,c  

^a DE MONTFORT UNIVERSITY   (United Kingdom)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c ASTRAZENECA   (United Kingdom)

Author keywords

3,4 methylenedioxymethamphetamine; 5 HT antagonists; 5 hydroxytryptamine; Dopamine; Dopamine antagonists; Ecstasy; Fluoxetine; GBR 12909; Hyperthermia

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE UPTAKE INHIBITOR; FLUOXETINE; GLEMANSERIN; METHYSERGIDE; REMOXIPRIDE; RITANSERIN; SEROTONIN UPTAKE INHIBITOR; VANOXERINE; ZIMELDINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG EFFECT; HIPPOCAMPUS; HYPERTHERMIA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONIN RELEASE;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; 3,4-METHYLENEDIOXYAMPHETAMINE; ACUTE DISEASE; ANIMALS; BODY TEMPERATURE; CORPUS STRIATUM; DOPAMINE; DOPAMINE ANTAGONISTS; DOPAMINE UPTAKE INHIBITORS; FEVER; HALLUCINOGENS; HIPPOCAMPUS; MALE; METHYSERGIDE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROPROTECTIVE AGENTS; PIPERAZINES; PIPERIDINES; RATS; RATS, INBRED STRAINS; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, SEROTONIN; REMOXIPRIDE; RITANSERIN; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 0036152649     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0704442     Document Type: Article

References (66)

1. Striatal dopamine release in vivo following neurotoxic doses of methamphetamine and the effect of the neuroprotective drugs chlormethiazole and dizocilpine
2. Attenuation by chlormethiazole administration of the rise in extracellular amino acids following focal ischaemia in the cerebral cortex of the rat
3. Ecstacy and dantrolene
4. The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine
5. Effects of sulpiride and SCH 23390 on methamphetamine-induced changes in body temperature and lethality
6. Multiple severe complications from recreational ingestion of MDMA ('esctasy')
7. Stereoselective N-oxygenation of zimeldine and homozimeldine by the flavin-containing monooxygenase
8. Changes in body temperature after administration of adrenergic and serotonergic agents and related drugs including antidepressants III
9. A study of the mechanism of MDMA ('Ecstasy')-induced neurotoxicity of 5-HT neurones using chlormethiazole, dizocilpine and other protective compounds
10. 5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine
11. Studies on the role of dopamine in the degeneration of 5-HT nerve endings in the brain of Dark Agouti rats following 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy') administration
12. In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA ('ecstasy') and p-chloroamphetamine but not the degeneration following fenfluramine
13. The hyperthermic and neurotoxic effects of Ecstasy (MDMA) and 3,4-methylenedioxymethamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP poor metabolizer phenotype
14. 2+ dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylenedioxymethamphetamine, p-chloro-amphetamine and (+)-fenfluramine
15. The effect of selective serotonin reuptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes
16. Effects of ambient temperature on hyperthermia and hyperkinesis induced by 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy') in rats
17. Ecstasy, a report of five deaths associated with the use of MDEA and MDMA
18. The effects of selective dopamine receptor agonists and antagonists on body temperature in rats
19. 2 receptors
20. Effects of 3,4-methylenedioxymethamphetamine on autonomic thermoregulatory responses of the rat
21. Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan
22. Inhibitory effect of chlorpromazine on the syndrome of hyperactivity produced by L-tryptophan or 5-methoxy-N, N-dimethyltyptamine in rats treated with a monoamine inhibitor
23. Vasodilatation and body warming
24. Effects of drugs on the processes regulating the functional activity of brain 5-hydroxytryptamine
25. 2 receptor agonists
26. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ('ecstasy')
27. Ecstasy and the dance of death
28. 3H]-dopamine release from superfused rat brain slices
29. MDMA induced dopamine release in vivo: Role of endogenous serotonin
30. The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine ('Ecstasy') in healthy volunteers
31. Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produce different effects on body temperature in the rat
32. MDMA induced hyperthermia: A survivor with an initial body temperature of 42.9 degrees C
33. Dopamine uptake inhibitors block long-term neurotoxic effects of methamphetamine
34. The effects of monoamine uptake inhibitors and methamphetamine on neostriatal 6-hydroxydopamine (6-OHDA) formation, short-term monoamine depletions and locomotor activity in the rat
35. Evidence for an alpha-1 receptor mediated central sympathoinhibitory action of ketanserin
36. Caveat emptor: Editors beware
37. Evidence against MDMA-induced hyperthermia being mediated by 5-HT release in the brain
38. A neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) to rats results in a long term defect in thermoregulation
39. 3,4-Methylenedioxymethamphetamine-induced acute change in dopamine transporter function
40. The interaction between the central and peripheral nervous systems in mediating the thermic effect of methamphetamine
41. The use of interspecies scaling in toxicokinetics
42. Effects of various dopamine uptake inhibitors on striatal extracellular dopamine levels and behaviours in rats
43. Ketanserin pretreatment attenuates MDMA-induced dopamine release in the striatum as measured by in vivo microdialysis
44. Microdialysis studies on 3,4methylenedioxymethamphetamine-induced dopamine release: Effect of dopamine uptake inhibitors
45. Elevation of serum prolactin and corticosterone concentrations after administration of 3,4-methylenedioxymethamphetamine
46. The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy')
47. Effect of GBR12909 and fluoxetine on the acute and long term change induced by MDMA ('ecstasy') on the 5-HT and dopamine concentrations in mouse brain
48. GBR 12909 antagonizes the ability of cocaine to elevate extracellular levels of dopamine
49. Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part I: Synaptosomal uptake and tissue concentrations
50. Reserpine attenuated Damphetamine and MDMA-induced transmitter release in vivo: A consideration of dose, core temperature and dopamine synthesis
51. The mechanisms involved in the long lasting neuroprotective effect of fluoxetine against MDMA ('ecstasy')-induced degeneration of 5-HT nerve endings in rat brain
52. Role of the dopamine uptake carrier in the neurochemical response to methamphetamine: Effects of amfonelic acid
53. Role of the serotonin uptake carrier in the neurochemical response to methamphetamine: Effects of citalopram and chlorimipramine
54. 2 receptors
55. 2 receptors exert a state-dependent regulation of dopaminergic function: Studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine
56. In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain
57. Methylenedioxymethamphetamine: A potentially neurotoxic amphetamine analogue
58. Hyperpyrexia and rhabdomyolysis after MDMA ('Ecstasy') abuse
59. A neurotoxic regimen of MDMA suppresses behavioral, thermal and neurochemical responses to subsequent MDMA administration
60. Methamphetamine-induced neurotoxicity. Roles for glutamate and dopamine efflux
61. Immediate and long term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat
62. The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain
63. Ecstasy and dantrolene
64. The acute effects of methylenedioxymethamphetamine on dopamine release in the awake-behaving rat
65. Dopaminergic and serotonergic mechanisms of thermoregulation: Mediation of thermal effects of apomorphine and dopamine